Emcitate® (tiratricol) Presentations at ETA and ESPE Congresses in September 2026

Stockholm, Sweden, September 4, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that clinical data relating to Emcitate® (tiratricol) for the treatment of MCT8 deficiency will be presented at the upcoming 47th Annual Meeting of the European Thyroid Association (ETA) in Porto, Portugal, and at the European Society for Paediatric Endocrinology (ESPE) 64th Annual Meeting in Marseille, France, in September 2026. The presentations include results from the Triac Trial II and ReTRIACt studies. ETA Annual Meeting, September 5-8, Porto, PortugalTitle: Effectiveness of early Triac treatment on neurocognitive outcomes in young paediatric male patients with MCT8 deficiency: TRIAC TRIAL IIPresenter: Floor van der Most, Erasmus Medical Center, Rotterdam, The NetherlandsPoster presentation: Saturday, September 5, 2026 Title: Effectiveness of early treatment with thyroid hormone analogue TRIAC on neurocognitive outcomes in young paediatric male patients with MCT8 deficiency: an international single arm trial Presenter: Floor van der Most, Erasmus Medical Center, Rotterdam, The NetherlandsOral presentation: Monday, September 7, 2026, Oral Session 11 (Luis Hall)Title: Effects of tiratricol treatment withdrawal in monocarboxylate transporter 8 (MCT8) deficiency: the ReTRIACt trialPresenter: Matthijs Freund, Erasmus Medical Center, Rotterdam, The NetherlandsOral presentation: Sunday, September 6, 2026, Oral Session 3 (Archive Hall) ESPE Annual Meeting, September 8-11, Marseille, FranceTitle: Effects of tiratricol treatment withdrawal in monocarboxylate transporter 8 (MCT8) deficiency: the ReTRIACt trial Presenter: Henna Oittinen Corbinelli, Head of Global Medical Affairs, Egetis Therapeutics, Stockholm, SwedenPoster presentation: Tuesday, September 8, 2026 (Poster ID P1508)

The release as fetched from its publisher. egetis.com ↗